Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
M.D. Anderson Cancer Center Sirtex Medical |
---|---|
Information provided by: | M.D. Anderson Cancer Center |
ClinicalTrials.gov Identifier: | NCT00766220 |
Primary Objective:
To determine the progression free survival for patients treated with the combination of liver directed therapy with SIR-Sphere followed by systemic chemotherapy with a combination of cetuximab with irinotecan for patients who have previously been treated.
Secondary Objectives:
Condition | Intervention | Phase |
---|---|---|
Colon Cancer Colorectal Cancer |
Drug: SIR-spheres Agent Administration Drug: Cetuximab Drug: Irinotecan Procedure: Blood vessel study |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Single Blind (Subject), Single Group Assignment, Safety/Efficacy Study |
Official Title: | Phase II Randomized Study of SIR-Spheres, Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Metastases to the Liver |
Estimated Enrollment: | 45 |
Study Start Date: | January 2009 |
Estimated Primary Completion Date: | October 2011 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Active Comparator
SIR-Spheres with Cetuximab + Irinotecan Therapy
|
Drug: SIR-spheres Agent Administration
SIR-Spheres, resin microspheres containing pure Beta emitter Yttrium-90, given through femoral catheter over 10 minutes
Drug: Cetuximab
Once a week by IV over 2 hours
Drug: Irinotecan
Once every 3 weeks by IV over 90 minutes
Procedure: Blood vessel study
X-Ray dye injected in artery through groin catheter to view arteries to liver and surrounding areas.
|
2: Active Comparator
Cetuximab + Irinotecan Therapy
|
Drug: Cetuximab
Once a week by IV over 2 hours
Drug: Irinotecan
Once every 3 weeks by IV over 90 minutes
Procedure: Blood vessel study
X-Ray dye injected in artery through groin catheter to view arteries to liver and surrounding areas.
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Ravi Murthy, MD | 713-745-0312 |
United States, Texas | |
UT MD Anderson Cancer Center | |
Houston, Texas, United States, 77030 |
Principal Investigator: | Ravi Murthy, MD | UT MD Anderson Cancer Center |
Responsible Party: | UT MD Anderson Cancer Center ( Ravi Murthy, MD/Associate Professor ) |
Study ID Numbers: | 2004-0779 |
Study First Received: | October 1, 2008 |
Last Updated: | December 1, 2008 |
ClinicalTrials.gov Identifier: | NCT00766220 |
Health Authority: | United States: Institutional Review Board |
colon liver Colorectal cancer Colorectal cancer metastases to the liver metastases to the liver colorectal cancer mets to liver colon cancer metastasized to liver |
Yttrium microspheres SIR-Spheres cetuximab irinotecan Yttrium 90 cetuximab plus irinotecan liver directed therapy |
Digestive System Neoplasms Gastrointestinal Diseases Colonic Diseases Irinotecan Cetuximab Intestinal Diseases Rectal Diseases |
Intestinal Neoplasms Digestive System Diseases Neoplasm Metastasis Gastrointestinal Neoplasms Colonic Neoplasms Colorectal Neoplasms |
Neoplasms Neoplasms by Site Molecular Mechanisms of Pharmacological Action Antineoplastic Agents |
Therapeutic Uses Enzyme Inhibitors Antineoplastic Agents, Phytogenic Pharmacologic Actions |